Bristol-Myers Squibb Overview

Trial Radar AI Insights

Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) stands as a premier global biopharmaceutical powerhouse focused on transforming the treatment landscape for serious diseases. The company maintains a strategic leadership position across oncology, hematology, immunology, and cardiovascular medicine, while aggressively expanding into neuroscience and targeted radiopharmaceuticals through high-value acquisitions. BMS leverages a multi-modal technology approach, ranging from small molecules and biologics to advanced cell therapies and protein degraders, to address significant unmet medical needs.

• Company Snapshot: Founded 1887; HQ Princeton, New Jersey, USA; Public (BMY); https://www.bms.com
• Scale & Stage: Employees ~34,100; Market Cap $115.26B; Commercial stage
• Research Focus: Oncology and Hematology; Immunology; Cardiovascular and Neuroscience
• Clinical Footprint: Active trials (lead sponsor): 195; Total participants: 117,913; Key geographies: United States, Japan, China, and Western Europe (plus 253 additional trials as collaborator)

Therapeutic Focus

Bristol-Myers Squibb prioritizes therapeutic areas where the biological rationale meets a high degree of medical necessity. The company’s "String of Pearls" strategy focuses on acquiring and developing assets that complement its core strengths in immuno-oncology and hematology while diversifying into high-growth areas like neuro-psychiatry and immunology.

• Primary Focus Areas:

  • Oncology & Hematology: Dominated by checkpoint inhibitors, CAR T-cell therapies (Abecma, Breyanzi), and next-generation protein degraders (CELMoDs) for multiple myeloma and solid tumors.
  • Immunology: Targeted treatments for autoimmune conditions like psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE) using TYK2 and CD19-targeted modalities.
  • Neuroscience: A renewed focus following the Karuna acquisition, targeting muscarinic receptors for schizophrenia and Alzheimer’s disease psychosis.

• Strategy & Capabilities:
  BMS integrates advanced computational biology and artificial intelligence to refine patient selection and optimize trial design. The company is transitioning its legacy portfolio toward subcutaneous formulations (e.g., Opdivo Qvantig) to improve patient convenience and extend product lifecycles. Its clinical maturity is evidenced by a robust Phase III pipeline that aims to replace revenue from upcoming patent expiries of foundational assets.

Bristol-Myers Squibb Pipeline and Products

Marketed Products

BMS manages a diverse portfolio of blockbuster therapies that define the standard of care across multiple indications.

Late-Stage Pipeline (Phase 2b+)

The late-stage pipeline features potential first-in-class therapies and significant expansions of existing brands.

Early-Stage Pipeline Highlights

BMS maintains a vigorous early-stage engine focused on novel platforms and mechanisms:

• BMS-986446 (anti-MTBR-tau): Currently in Phase II for Alzheimer's disease, this antibody targets the microtubule-binding region of tau. It received FDA Fast Track Designation in October 2025 to accelerate its development as a potential disease-modifying therapy.
• CD19 NEX-T: A next-generation CAR T-cell therapy utilizing a shortened manufacturing process designed for rapid deployment in autoimmune diseases like Systemic Lupus Erythematosus (SLE).
• Pumitamig (BNT327): A PD-L1 x VEGF-A bispecific antibody partnered with BioNTech. Early Phase II data in triple-negative breast cancer (TNBC) showed a 62% confirmed objective response rate, leading to the initiation of Phase III ROSETTA trials in January 2026.

Bristol-Myers Squibb Clinical Trials Landscape

Trial StatisticsApply Below Filters

Bristol-Myers Squibb manages 195 active clinical trials as lead sponsor, targeting an enrollment of 117,913 participants across 12,948 global study locations as of February 2026. The portfolio is heavily weighted toward late-stage development, with 64 trials in Phase III and 47 in Phase II, reflecting a focus on registrational readouts. Clinical activity is most concentrated in the United States, Japan, and China, with Rheumatoid Arthritis and Multiple Sclerosis representing the largest enrollment populations.

Key Clinical Trial Updates

• Obexelimab: Reported positive Phase III INDIGO results in January 2026, demonstrating a 56% reduction in the risk of flares for patients with IgG4-Related Disease.
• Milvexian: The Phase III LIBREXIA-ACS trial was terminated in November 2025 following an interim analysis; however, pivotal trials for Atrial Fibrillation and Secondary Stroke Prevention remain active with data expected in late 2026.
• Cobenfy (KarXT): Enrollment for the ADEPT-2 trial in Alzheimer’s disease psychosis was expanded in December 2025 to compensate for site-level execution issues, with the readout now anticipated in the second half of 2026.
• Sotyktu: The FDA is currently reviewing an sNDA for Psoriatic Arthritis, with a PDUFA goal date of March 6, 2026.

Business Insights and Analysis

Business Development

BMS has executed a series of transformative M&A transactions to replenish its pipeline. The $14 billion acquisition of Karuna Therapeutics (March 2024) secured Cobenfy, while the $4.1 billion acquisition of RayzeBio (February 2024) provided a leading targeted radiopharmaceutical platform. Strategic partnerships remain central to its growth; notably, the $8.4 billion total deal value collaboration with SystImmune for the EGFR x HER3 ADC (iza-bren) positions BMS as a major player in the antibody-drug conjugate space.

Financial Overview

Bristol-Myers Squibb maintains a robust investment-grade balance sheet with a market capitalization of approximately $115.26 billion. While the company faces upcoming generic competition for Revlimid and Eliquis, its "New Product Portfolio"—comprising Opdualag, Camzyos, Sotyktu, and Cobenfy—is projected to provide significant revenue offsets through 2030.

Clinical Trial Participation Guide

Trial Radar provides the tools necessary to navigate Bristol-Myers Squibb’s extensive clinical portfolio.

• Participation Assistant: Use the "Simplify" feature to break down complex protocols, "What to Expect" to understand the trial journey, and "Check Eligibility" to see if you meet the specific requirements for a study.
• Contacts & Locations: Navigate to the dedicated tab to identify the nearest active research site and find direct contact information for study coordinators.

Explore Bristol-Myers Squibb clinical trials

See 50 of 2,765 studies.